Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates in lieu of the original share certificates reported lost/misplaced, details of which are enclosed. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed. World Coronavirus Dispatch: Students across globe returning to classrooms
Boris Johnson earmarks 500 mn for mass rapid testing, Sanofi starts trials of vaccine, Steroids could reduce deaths by a third, and other pandemic-related news across the globe World Coronavirus Dispatch: US crosses six mn mark, cases in sun belt ease
WHO warns against opening up without control of Covid, Hong Kong begins mass testing, Sanofi's Kevzara drug fails as possible treatment and other pandemic-related news across the globe Coronavirus vaccine: Sanofi more confident about its vaccines; trials next month
The company is working on two of the more than 150 potential vaccines being developed across the world to tackle the COVID-19 pandemic Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates in lieu of the original share certificates reported lost/misplaced, details of which are enclosed. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed. Sanofi India Ltd - 500674 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (Listing Regulations)
The unaudited financial results of the Company for the quarter and half year ended 30th June 2020 were approved by the Board of Directors of the Company at its meeting held on 28th July 2020 and published on 30th July 2020. Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed the disclosures of related party transactions for the half year ended 30th June 2020 in the format specified in the applicable accounting standards. Sanofi India gains 5%, hits 52-week high; stock soars 8% so far in August
Early this week, the comany's parent firm Sanofi said it will acquire all of the outstanding shares of US-based Principia Biopharma Inc. for a total approximate aggregate equity value of $3.68 billion Sanofi begins M&A spree; to purchase Principia Biopharma at $3.7 billion
The French group already owns the licensing rights to Principia's key multiple sclerosis drugs, which should give it a clearer view on its prospects